Data gathered: May 29
AI Stock Analysis - Novavax (NVAX)
Analysis generated November 29, 2024. Powered by Chat GPT.
Novavax, Inc. is a biotechnology company focused on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company has gained significant attention for its work on the COVID-19 vaccine, alongside other vaccine candidates targeting various illnesses.
Stock Alerts - Novavax (NVAX)
 |
Novavax | May 21 Price is down by -7% in the last 24h. |
|
Novavax | May 19 Price is up by 22.7% in the last 24h. |
|
Novavax | May 16 Price is up by 7.3% in the last 24h. |
|
Novavax | May 13 Business Outlook among employees is down by 6.9% over the last month. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Novavax
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 44,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 25 | Sign up | Sign up | Sign up |
| Patents | 38 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 4 | Sign up | Sign up | Sign up |
| Facebook Followers | 40,052 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1,733 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 106,051 | Sign up | Sign up | Sign up |
| Twitter Followers | 60,822 | Sign up | Sign up | Sign up |
| Twitter Mentions | 386 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,140 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $50,000 | Sign up | Sign up | Sign up |
| Business Outlook | 27 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,141 | Sign up | Sign up | Sign up |
About Novavax
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases.
| Price | $7.20 |
| Target Price | Sign up |
| Volume | 4,150,000 |
| Market Cap | $1.2B |
| Year Range | $5.43 - $14.68 |
| Dividend Yield | 0% |
| PE Ratio | 2.68 |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
Novavax Inc - Eliminates COO Position, Terminates John Trizzino - SEC FilingMay 27 - Finnhub |
|
 |
Novavax, Inc. (NASDAQ:NVAX) Stock Holdings Reduced by Lazard Asset Management LLCMay 27 - ETF Daily News |
FDA Approves BLA For Novavax's COVID-19 VaccineMay 26 - Finnhub |
|
|
ProShare Advisors LLC Boosts Stake in Novavax, Inc. (NASDAQ:NVAX)May 26 - ETF Daily News |
 |
Here's Why Novavax (NVAX) is a Strong Momentum StockMay 25 - Yahoo |
|
Novavax, Inc. (NASDAQ:NVAX) Receives $19.00 Average PT from BrokeragesMay 25 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 667M | 14M | 653M | 519M | 516M | 2.930 |
| Q4 '24 | 88M | 37M | 52M | -81M | -53M | -0.520 |
| Q3 '24 | 85M | 61M | 24M | -121M | -105M | -0.758 |
| Q2 '24 | 415M | 36M | 379M | 162M | 180M | 0.990 |
| Q1 '24 | 94M | 49M | 45M | -148M | -129M | -1.050 |
Insider Transactions View All
| YOUNG JAMES F filed to sell 51,760 shares at $8. January 2 '25 |
| YOUNG JAMES F filed to sell 57,160 shares at $8.5. January 2 '25 |
| King Rachel K. filed to sell 14,770 shares at $9. January 2 '25 |
| YOUNG JAMES F filed to sell 61,760 shares at $14.1. June 25 '24 |
| YOUNG JAMES F filed to sell 69,260 shares at $14.3. June 21 '24 |
Similar companies
Read more about Novavax (NVAX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novavax?
The Market Cap of Novavax is $1.2B.
What is Novavax's PE Ratio?
As of today, Novavax's PE (Price to Earnings) ratio is 2.68.
What is the current stock price of Novavax?
Currently, the price of one share of Novavax stock is $7.20.
How can I analyze the NVAX stock price chart for investment decisions?
The NVAX stock price chart above provides a comprehensive visual representation of Novavax's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novavax shares. Our platform offers an up-to-date NVAX stock price chart, along with technical data analysis and alternative data insights.
Does NVAX offer dividends to its shareholders?
As of our latest update, Novavax (NVAX) does not offer dividends to its shareholders. Investors interested in Novavax should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Novavax?
Some of the similar stocks of Novavax are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.